ASAH2 Polyclonal Antibody

ASAH2 Polyclonal Antibody

The ASAH2 Polyclonal Antibody is a highly specific and sensitive tool designed for the detection and quantification of ASAH2 protein in various biological samples. This antibody has been meticulously developed using advanced techniques to ensure exceptional performance and reliability.

ASAH2, also known as acid ceramidase 2, is a crucial enzyme involved in the metabolism of sphingolipids. It plays a vital role in the hydrolysis of ceramide into sphingosine and free fatty acids, thereby regulating cellular processes such as apoptosis, cell proliferation, and inflammation. Dysregulation of ASAH2 has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.

The ASAH2 Polyclonal Antibody exhibits high affinity and specificity towards ASAH2 protein, enabling accurate detection and quantification in a wide range of sample types, including cell lysates, tissue homogenates, and biological fluids. It has been rigorously validated for use in various applications, including Western blotting, immunohistochemistry, and enzyme-linked immunosorbent assays (ELISA).

This antibody offers exceptional sensitivity, allowing for the detection of low levels of ASAH2 protein, even in samples with limited quantities. Its robust performance ensures reliable and reproducible results, making it an ideal choice for both research and diagnostic applications.

The ASAH2 Polyclonal Antibody is supplied as a liquid formulation, ready for immediate use. It is provided in a convenient size and format, allowing for easy handling and storage. Each batch of antibody undergoes stringent quality control measures to ensure consistent performance and batch-to-batch reproducibility.

In summary, the ASAH2 Polyclonal Antibody is a highly reliable and specific tool for the detection and quantification of ASAH2 protein. Its exceptional sensitivity, robust performance, and versatile applications make it an invaluable asset for researchers and clinicians alike in their quest to unravel the complexities of ASAH2-related diseases.